Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study [0.03%]
对于MSS/pMMR局部晚期直肠癌，术前新辅助化疗联合PD-1抑制剂和IL-2的短期疗效：一项单臂二期临床试验的初步结果
Junwei Tang,Lu Wang,Sheng Yang et al.
Junwei Tang et al.
Neoadjuvant therapy has become a cornerstone in the management of locally advanced rectal cancer (LARC). In this single-arm, open-label phase II study, we evaluated the efficacy and safety of total neoadjuvant chemotherapy (TNT) using a Cap...
Harnessing pre-existing measles immunity: mRNA-Lipid nanoparticle-mediated measles hemagglutinin expression boosts antitumor CD8⁺ T cell responses [0.03%]
利用既往存在的麻疹病毒免疫性：mRNA-脂质纳米颗粒介导的麻疹血凝素表达增强抗肿瘤CD8⁺T细胞反应
Javier Martínez-Latorre,Paula M Soriano-Teruel,Vicente Candela-Noguera et al.
Javier Martínez-Latorre et al.
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer [0.03%]
单细胞成像分析、治疗模型及Ⅱb期临床试验验证BCL-2是异质性去势抵抗性前列腺癌的治疗靶点
Anmbreen Jamroze,Xiaozhuo Liu,Surui Hou et al.
Anmbreen Jamroze et al.
BCL-2 has been implicated in prostate cancer (PCa) progression and development of castration-resistant disease (CRPC); however, it remains unclear how the BCL-2- and AR-expressing PCa cell populations evolve across the PCa continuum, how AR...
Bone morphogenetic protein signaling drives rete ridge morphogenesis: a distinct epidermal appendage program [0.03%]
骨形态发生蛋白信号驱动毛囊ridge形态发生：一种独特的皮肤附属器官程序
Dong Gil Lee,Sun-Uk Kim,Young-Ho Park
Dong Gil Lee
BMAL1 regulates circadian rhythms via phase separation-mediated transcriptional hub formation [0.03%]
昼夜节律调节依赖于BMAL1介导的转录调控相分离簇形成
Wenzhen Gao,Li Zhu,Yali Wei et al.
Wenzhen Gao et al.
The mechanisms by which core clock components are spatially organized to ensure robust oscillations in mammals remain unclear. Here, we identify the positive limb factor BMAL1 as a phase-separating protein that forms dynamic biomolecular co...
Correction to: Extraocular delivery of bioswitchable tri-miR-22-loaded tetrahedral DNA nanostructures for intraocular neovascular and neurodegenerative repair [0.03%]
题为《用于眼内新生血管和神经退行性修复的生物可切换三miR-22载四面体DNA纳米结构的非眼部递送》的 corrections
Qiong Wang,You Wang,Li Chen et al.
Qiong Wang et al.
MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth [0.03%]
靶向MARCO通过诱导免疫抑制从而减少胆管细胞癌的生长促进肝内胆管癌进展的作用及机制研究
Aloña Agirre-Lizaso,Maider Huici-Izagirre,Colm J O&#x;Rourke et al.
Aloña Agirre-Lizaso et al.
Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary malignant tumors with poor prognosis and limited therapeutic options. Recent studies have highlighted the role of the immune system in the development and progression of in...
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer [0.03%]
靶向损伤相关巨噬细胞中的GPR34可增强抗肿瘤免疫并提高索凡替尼在胰腺癌中的疗效
Xiaofan Guo,Yuxiao Liu,Tianchen Li et al.
Xiaofan Guo et al.
Tumor-associated macrophages (TAMs) are pivotal in the immunosuppressive tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). The efficacy of targeting the CSF-1/CSF-1R axis in PDAC remains uncertain. Using single-cell RNA seq...
Drugging the intrinsically disordered transactivation domain of androgen receptor [0.03%]
靶向作用于雄激素受体内在无序转录激活域的药物研究进展
Jon K Obst,Carmen A Banuelos,Kunzhong Jian et al.
Jon K Obst et al.
Androgen receptor (AR) is a therapeutic target for prostate cancer. Despite effectively targeting its folded ligand-binding domain (LBD), resistance ultimately develops by mechanisms involving reactivation of AR signaling. These mechanisms ...
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study [0.03%]
一项关于复发或难治滤泡性淋巴瘤患者使用Abexinostat（组蛋白去乙酰化酶抑制剂）的多中心、单臂二期临床试验
Lin Gui,Haifeng Liu,Huaqing Wang et al.
Lin Gui et al.
This phase 2, single-arm, multi-center study (NCT03934567) evaluates the efficacy and safety of abexinostat, a histone deacetylase inhibitor, in patients with relapsed or refractory (r/r) follicular lymphoma (FL). Eligible participants had ...